RS Investment Management’s Immunic IMUX Stock Holding History

RS Investment Management’s Portfolio IMUX Stock Details IMUX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	$13.5M	Sell	5,441 -404	-7%	-$1.33M	0.14%	224
2016 Q1	$21.2M	Buy	5,845 +423	+8%	+$1.47M	0.21%	169
2015 Q4	$25M	Buy	5,422 +1,371	+34%	+$4.47M	0.22%	156
2015 Q3	$6.55M	Sell	4,051 -129	-3%	-$645K	0.06%	254
2015 Q2	$35.3M	Buy	4,180 +1,448	+53%	+$13.8M	0.3%	125
2015 Q1	$27.3M	Buy	2,732 +310	+13%	+$2.85M	0.24%	153
2014 Q4	$24.2M	Buy	2,422 +932	+63%	+$7.18M	0.22%	164
2014 Q3	$12.2M	Buy	1,490 +64	+4%	+$604K	0.11%	218
2014 Q2	$15.5M	Buy	+1,426	New	+$10M	0.13%	201

Other funds holding IMUX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Truvvo Partners New York $5.22M AUM 13.74% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BIM

BlackRock Investment Management Wilmington, Delaware $86.4B AUM 16.83% 1-Year Est. Return

RS Investment Management's IMUX Position: Q2 2016 in Review

RS Investment Management reduced its Immunic (IMUX) stake by 6.9% in Q2 2016, selling an estimated $1.33M and leaving 5,441 shares worth $13.5M. The position accounts for 0.14% of the portfolio, ranked #224.

RS Investment Management first reported a position in IMUX in Q2 2014 and has held it in 9 quarters since. The position peaked at $35.3M in Q2 2015. 54 funds tracked by Wall St. Rank hold IMUX as of Q2 2016.

RS Investment Management held 5,441 shares of Immunic worth $13.5M as of Q2 2016.
RS Investment Management sold 404 Immunic shares in Q2 2016, an estimated $1.33M.
Immunic made up 0.14% of RS Investment Management's portfolio in Q2 2016, its #224 holding.
RS Investment Management first reported a position in Immunic in Q2 2014 and has held it in 9 quarters since.
RS Investment Management's Immunic position peaked at $35.3M in Q2 2015.
54 funds tracked by Wall St. Rank held Immunic as of Q2 2016.

Based on RS Investment Management's 13F filing for Q2 2016, filed 26 Jul 2016.